PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30650200-0	2019	Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.	OSI 027	24-31	CREB regulated transcription coactivator 1	Mus musculus	10-16	
30650200-6	2019	Further, OSI-027 almost completely blocked the phosphorylation of the mTORC1 substrates, S6K1, S6 and 4EBP1, and the mTORC2 substrate, AKT, at Ser-473.	OSI 027	9-16	CREB regulated transcription coactivator 1	Mus musculus	70-76	
30650200-7	2019	The OSI-027 treatment of keloid keratinocytes showed more effectively inhibited cell proliferation and migration compared to the mTORC1 inhibitor, rapamycin.	OSI 027	4-11	CREB regulated transcription coactivator 1	Mus musculus	129-135	
30650200-8	2019	Moreover, restoring mTORC1 activation by the introduction of the constitutively active S6K1 only partly alleviated OSI-027-induced inhibition of keloid keratinocytes.	OSI 027	115-122	CREB regulated transcription coactivator 1	Mus musculus	20-26	
30650200-10	2019	Together, our results imply that concurrent targeting of mTORC1/2 by OSI-027 potently inhibits the proliferation and the migration of keloid keratinocytes.	OSI 027	69-76	CREB regulated transcription coactivator 1	Mus musculus	57-63	
27358039-2	2016	Here, we report that the dual mTORC1/2 inhibitors PP242 and OSI-027 decreased cell viability but did not induce apoptosis in the non-small cell lung cancer (NSCLC) cell lines H460 and A549.	OSI 027	60-67	CREB regulated transcription coactivator 1	Mus musculus	30-36	
27212159-11	2016	CONCLUSIONS: Dual mTORC1/mTORC2 inhibitors such as OSI-027 are promising therapeutic agents in combination with 5-FU for the treatment of human gallbladder cancer.	OSI 027	51-58	CREB regulated transcription coactivator 1	Mus musculus	18-24	
27002938-0	2016	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.	OSI 027	66-73	CREB regulated transcription coactivator 1	Mus musculus	42-48	
26284306-0	2015	The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.	OSI 027	38-45	CREB regulated transcription coactivator 1	Mus musculus	83-89	
26284306-5	2015	At the molecular level, OSI-027 treatment blocked mTORC1 and mTORC2 activation simultaneously, without affecting ERK-mitogen-activated protein kinase activation.	OSI 027	24-31	CREB regulated transcription coactivator 1	Mus musculus	50-56	
26213847-2	2015	In this study, we investigated the in vitro efficacy of OSI-027, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2, to treat PDAC cell lines alone, and in combination with gemcitabine (GEM).	OSI 027	56-63	CREB regulated transcription coactivator 1	Mus musculus	131-137	
26026051-4	2015	In this study, we examined the interaction between the dual mTORC1/2 inhibitor OSI-027 and doxorubicin in vitro and in vivo.	OSI 027	79-86	CREB regulated transcription coactivator 1	Mus musculus	60-66	
26026051-5	2015	OSI-027 was found to reduce phosphorylation of both mTORC1 and mTORC2 substrates, including 4E-BP1, p70S6K, and AKT (Ser473), and inhibit HCC cell proliferation.	OSI 027	0-7	CREB regulated transcription coactivator 1	Mus musculus	52-58	
26026051-11	2015	Our findings provide a rationale for dual mTORC1/mTORC2 inhibitors, such as OSI-027, as monotherapy or in combination with cytotoxic agents to treat HCC.	OSI 027	76-83	CREB regulated transcription coactivator 1	Mus musculus	42-48	
22476852-4	2012	We demonstrated that inhibition of mTORC1/2 by mTOR kinase inhibitors PP242 and OSI-027 effectively suppress phosphorylation of Akt (S473) and breast cancer cell proliferation.	OSI 027	80-87	CREB regulated transcription coactivator 1	Mus musculus	35-41	
22080480-7	2012	Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, up-regulated Puma, and induced regressions in Jeko xenografts.	OSI 027	10-17	CREB regulated transcription coactivator 1	Mus musculus	47-53	
21673091-0	2011	Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.	OSI 027	32-39	CREB regulated transcription coactivator 1	Mus musculus	77-83	
21673091-4	2011	Here, we report the preclinical characterization of OSI-027, a selective and potent dual inhibitor of mTORC1 and mTORC2 with biochemical IC(50) values of 22 nmol/L and 65 nmol/L, respectively.	OSI 027	52-59	CREB regulated transcription coactivator 1	Mus musculus	102-108	
21673091-6	2011	OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo.	OSI 027	0-7	CREB regulated transcription coactivator 1	Mus musculus	40-46	
21415215-8	2011	Inhibition of the mTOR catalytic site with OSI-027 results in suppression of both mTORC2 and RI-mTORC1 complexes and elicits much more potent antileukemic responses than selective mTORC1 targeting with rapamycin.	OSI 027	43-50	CREB regulated transcription coactivator 1	Mus musculus	96-102	
21363918-4	2011	ATP-competitive inhibitors OSI-027 and OXA-01 targeted both mTORC1 and mTORC2 signaling in vitro and in vivo, unlike rapamycin that only inhibited mTORC1 signaling.	OSI 027	27-34	CREB regulated transcription coactivator 1	Mus musculus	60-66	
20699667-3	2010	We have recently shown that dual targeting of mTORC1 and mTORC2 complexes using a catalytic mTOR inhibitor, OSI-027, results in generation of potent antileukemic effects against BCR-ABL transformed cells.	OSI 027	108-115	CREB regulated transcription coactivator 1	Mus musculus	46-52	
20616057-4	2010	Our studies establish that a unique dual mTORC2/mTORC1 inhibitor, OSI-027, induces potent suppressive effects on primitive leukemic progenitors from CML patients and generates antileukemic responses in cells expressing the T315I-BCR-ABL mutation, which is refractory to all BCR-ABL kinase inhibitors currently in clinical use.	OSI 027	66-73	CREB regulated transcription coactivator 1	Mus musculus	48-54	
33222668-7	2021	At the molecular level, OSI-027 simultaneously blocked mTORC1 and mTORC2 activation, and resulted in the downregulation of phosphor-Akt, phpspho-p70S6k, phosphor-4EBP1, cyclin D1, and cyclin-dependent kinase4 (CDK4).	OSI 027	24-31	CREB regulated transcription coactivator 1	Mus musculus	55-61	
33222668-10	2021	In summary, our results suggest that dual mTORC1/mTORC2 inhibitors (e.g., OSI-027) should be further investigated as a potential valuable treatment for gastric cancer.	OSI 027	74-81	CREB regulated transcription coactivator 1	Mus musculus	42-48